Summary of Inventiva FY Conference Call (March 02, 2026) Company Overview - **Company**: Inventiva (NasdaqGM: IVA) - **Focus**: Ongoing phase three NATiV3 trial for NASH (Non-Alcoholic Steatohepatitis) treatment Key Points Industry and Product Insights - **NASH Market**: The NASH market is competitive, with existing players showing modest effect sizes. Inventiva aims to demonstrate a significant improvement in fibrosis and NASH resolution through its drug, lanifibranor [1][2] - **Phase Three NATiV3 Trial**: The trial is designed similarly to the previous NATIVE two trial, focusing on a combined primary endpoint of fibrosis and NASH resolution. The trial excludes F1 patients, potentially providing a competitive advantage [6][9] - **Expected Outcomes**: A target of approximately 20% effect on fibrosis is anticipated, which could significantly disrupt the current market by doubling existing effect sizes [9][10] Clinical Data and Safety - **Previous Trials**: The NATIVE two trial showed a 24% dual endpoint resolution and 18% fibrosis improvement at six months, setting a benchmark for NATiV3 [6][10] - **Safety Concerns**: Previous safety issues related to hepatic events have been addressed, with ongoing monitoring and assessments showing no significant concerns in the current trial [16][21] - **Weight Gain and Tolerability**: In phase IIb, 50% of patients showed no weight gain, while one-third experienced over 5% weight gain. The company emphasizes that treatment efficacy is not dependent on weight gain [26][37] Market Strategy and Commercialization - **Pre-commercialization Efforts**: A chief commercial strategy officer has been appointed to enhance market access and engage with key opinion leaders (KOLs) [73][80] - **Target Population**: The diabetic NASH population is identified as a significant opportunity, with about 70% of NASH patients also having diabetes. The company plans to focus on the full spectrum of F2 and F3 patients, including those with type 2 diabetes [210][217] Future Trials and Regulatory Considerations - **F4 MASH Confirmatory Trial**: Plans for a confirmatory trial in F4 MASH are in place, with the requirement to run an outcome study for full approval. The trial is expected to start around the time of the NDA filing in 2027 [94][104] - **Patient Selection**: The strategy involves enrolling patients with significant portal hypertension to ensure a higher event rate, which is crucial for powering the trial [135][144] Financial Position - **Cash Position**: As of the end of 2025, the company has EUR 231 million in cash, projected to last through Q3 2027, assuming positive trial data. A EUR 149 million raise was completed in November 2025 [195][196] Combination Therapies - **Potential for Combination**: Lanifibranor's unique mechanism allows for potential combination therapies, particularly with GLP-1s for diabetes management and cardiovascular risk reduction [197][205] Additional Insights - **Market Dynamics**: The company acknowledges the evolving landscape of combination therapies in the NASH space and is open to exploring these opportunities as data becomes available [197][205] - **Investor Communication**: The company aims to provide clear guidance on trial data and market strategies as they progress through the year [39][56] This summary encapsulates the key discussions and insights from the Inventiva FY Conference Call, highlighting the company's strategic direction, clinical trial progress, and market positioning in the NASH treatment landscape.

Summary of Reibo Bio's Conference Call Company Overview - **Company**: Reibo Bio - **Industry**: Biotechnology, specifically focusing on NASH (Non-Alcoholic Steatohepatitis) treatment Key Points and Arguments Collaboration with Madrigal - Reibo Bio has entered into a collaboration with Madrigal in the NASH field, receiving an upfront payment of $60 million and potential milestone payments exceeding $4.4 billion, along with sales royalties based on annual revenue [2][3] - This partnership accelerates the global development of Reibo Bio's related assets [2] Multi-Target Strategy in NASH - Reibo Bio employs a multi-target strategy in the NASH area, focusing on cardiovascular, renal, and metabolic diseases, ensuring complementary targets with partners like Boehringer Ingelheim and Madrigal [2][4][5] - The company aims to achieve at least one IND (Investigational New Drug) application in the NASH field within the next two years, potentially generating tens of millions in milestone revenue [2][11] Advantages of Small RNA Therapy - Madrigal views small RNA therapy as having significant potential in preventive treatment for NASH, with a dosing regimen of one to two injections per year being a major improvement over existing oral medications [2][6] - The collaboration is expected to solidify Madrigal's market position and explore combination therapies [6] Strategic Importance of the Collaboration - The partnership allows Reibo Bio to quickly enter the NASH treatment market, leveraging Madrigal's extensive R&D and commercialization experience [2][7] - This collaboration reflects international recognition of Reibo Bio's technical capabilities and asset layout, facilitating faster global development of related assets [7] Clinical Development Challenges - The clinical development in the NASH field is challenging due to strict FDA requirements, including the need for invasive liver biopsies to validate efficacy [16][17] - The cost of enrolling a patient can reach $100,000 before any experimental treatment, adding to the complexity of clinical trials [17] Future Clinical Plans and Milestones - Reibo Bio plans to initiate multiple clinical trials for new delivery technologies in 2026 and 2027, although these are not included in the current collaboration [10] - The company has set multiple milestones related to R&D, regulatory, and sales aspects within the collaboration agreement [11] Business Development Focus - Reibo Bio emphasizes business development and has made significant progress, including collaborations with companies like MacroGenics [20] - The company is actively preparing and advancing multiple business development projects [20] Overall Strategic Direction - Reibo Bio's current projects leverage its technological platform, aiming to accelerate the global development of assets in the NASH field [21][22] - The company will continue to focus on independent R&D while exploring various collaboration models to maximize shareholder value [22]

Summary of Madrigal Pharmaceuticals (MDGL) Conference Call on May 13, 2025 Company Overview - **Company**: Madrigal Pharmaceuticals - **Focus**: Development of treatments for Non-Alcoholic Steatohepatitis (NASH) and related liver diseases - **Key Product**: Risdipla (Resmeterome), FDA approved for NASH with moderate to advanced fibrosis (F2 and F3) Industry Context - **Disease**: Compensated mass cirrhosis (F4C) is a high-risk stage of NASH with no FDA approved treatments - **Market Opportunity**: Expansion into F4C could potentially double the market opportunity for Risdipla Core Points and Arguments 1. **Understanding F4C**: F4C patients are severely ill but still retain some liver function, facing serious risks once clinically significant portal hypertension (CSPH) develops [5][6][8] 2. **Clinical Data Presentation**: New findings from the two-year open-label MAESTRO NAFLD-1 trial were shared, showing Risdipla's broad and consistent effects [6][10] 3. **Pivotal Phase III Trial**: The MAESTRO NASH outcomes trial is designed to evaluate Risdipla's ability to reduce liver-related events in F4C patients, with results expected in 2027 [7][48] 4. **Efficacy of Risdipla**: In phase three trials, Risdipla halted or improved liver stiffness in 91% of patients, with over 17,000 patients treated by Q1 2025 [9][10] 5. **Mechanism of Action**: Risdipla targets fat, inflammation, and fibrosis through THR beta activation, which is crucial for liver metabolism [12][24] 6. **Clinical Outcomes**: The trial showed that 65% of patients with CSPH at baseline moved to a lower risk category after treatment, indicating a significant clinical benefit [19][57] 7. **Safety Profile**: Risdipla was well tolerated, with common adverse events similar to non-cirrhotic populations, and a low discontinuation rate of 2.5% [41][43] Important but Overlooked Content 1. **Patient Population Characteristics**: The trial included patients with lower platelet counts, indicating a more advanced disease state, which is critical for understanding the treatment's impact [55][68] 2. **Long-term Outcomes**: The potential for sustained improvement in liver stiffness and reduction in CSPH risk categories over time is emphasized, with a focus on preventing decompensation [69][70] 3. **Comparison with Competitors**: The call highlighted the importance of Risdipla's unique mechanism compared to other treatments in development, such as FGF21s, and the need for further education among community gastroenterologists [60][81] Conclusion - **Future Outlook**: Madrigal Pharmaceuticals is positioned to lead in the treatment of NASH and F4C, with Risdipla showing promising clinical data and a strong safety profile. The company aims to solidify its role as a foundational therapy for patients across the spectrum of liver disease [48][49]

Financial Data and Key Metrics Changes - For Q1 2025, net sales totaled $137.3 million, representing a 33% increase from Q4 2024 [30] - Over the last twelve months, the company generated $317 million in net sales, indicating strong demand and momentum [28][30] - R&D expenses decreased to $44.2 million in Q1 2025 from $71.2 million in Q1 2024, primarily due to changes in accounting for inventory costs and lower clinical trial costs [31] - SG&A expenses increased to $167.9 million in Q1 2025 from $80.8 million in Q1 2024, driven by increased commercial launch activities [32] Business Line Data and Key Metrics Changes - The company has treated over 17,000 patients with ResDiffera, up from 11,800 patients at the end of Q4 2024, indicating strong patient adoption [12] - Approximately 70% of the top 6,000 target prescribers have prescribed ResDiffera, reflecting a strong base of prescribers [15] - The company is focused on a target market of 315,000 diagnosed F2 and F3 MAH patients, with only about 5% currently being treated with ResDiffera [13] Market Data and Key Metrics Changes - The company is preparing for a mid-year regulatory decision in Europe, with plans to launch in Germany in the second half of the year if approved [26] - The company is evaluating additional high-priority global markets beyond Europe [26] Company Strategy and Development Direction - The expansion to treat F4C patients is a key pillar of the company's long-term NASH leadership strategy, with ongoing trials expected to yield data ahead of competitors [25] - The company aims to build a portfolio of differentiated assets to extend its leadership position in the market [27][90] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's positioning within the current macroeconomic environment, highlighting the strong cash position to support ongoing launches [29] - The company expects robust year-over-year net sales growth in 2025, despite anticipated increases in gross-to-net discounts as payer contracts are established [30][31] Other Important Information - The company has recently appointed a new Chief Medical Officer, Dave Sorgel, to lead pipeline development efforts [9][27] - The company is actively evaluating opportunities across multiple mechanisms and stages of development to enhance its product offerings [27] Q&A Session Summary Question: Expectations for growth trajectory for ResDiffera with expanded label - Management expects continued growth in patient numbers and market expansion, with significant potential for new patient additions as the market evolves [39][40] Question: Payer reauthorization requirements and patient persistency - Management is not concerned about reauthorizations, citing strong results and patient feedback, which should support persistency [45][47] Question: Status of European approval and implications for pricing - Management is optimistic about the ongoing review process in Europe and expects to launch later this year, with pricing strategies being evaluated [53][56] Question: Confidence in outcomes benefit on hepatic events - Management expressed confidence in the liver stiffness data translating to clinical outcomes, supported by the mechanism of action of ResDiffera [62] Question: Compliance rates and patient feedback on therapy - Early signs of adherence are promising, with anecdotal evidence suggesting patients feel better on the therapy [66][69] Question: Insights on gross-to-net pricing evolution - Management anticipates a disciplined approach to gross-to-net pricing, with ongoing discussions with payers [106][108]